Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Teddy Pan

Dermatopathology Colonie, NY Medical Doctor

NPI 1609847979 CMS profile 117691

105 Everett Rd, Colonie, NY 12205

Open in the dashboard

General payments

$2,295

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teddy Pan of Colonie, NY is reported in the CMS Open Payments database as having received $2,295 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Dermatopathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $777 37
2023 General $625 29
2022 General $293 11
2021 General $20 1
2020 General $84 5
2019 General $497 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teddy Pan
  • Dermatopathology median
  • Middle half of Dermatopathology
  • National median

In program year 2025, general payments to Teddy Pan were reported at $777. Among 238 Dermatopathology profiles paid that year, the median was $251 and the middle half received between $93 and $1,140.

Show as a table
Year Teddy Pan Dermatopathology median Middle half National median
2019 $497 $295 $101–$807 $163
2020 $84 $154 $53–$443 $114
2021 $20 $226 $66–$781 $132
2022 $293 $258 $76–$906 $149
2023 $625 $303 $93–$1,129 $160
2024 $0 $324 $101–$1,343 $164
2025 $777 $251 $93–$1,140 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $711 37 payments
  2. AbbVie, Inc. $218 9 payments
  3. Sun Pharmaceutical Industries Inc. $218 10 payments
  4. Novartis Pharmaceuticals Corporation $175 8 payments
  5. Genzyme Corporation $146 6 payments
  6. Regeneron Healthcare Solutions, Inc. $122 6 payments
  7. LEO Pharma Inc. $108 4 payments
  8. E.R. Squibb & Sons, L.L.C. $93 5 payments
  9. Pfizer Inc. $86 4 payments
  10. Amgen Inc. $62 4 payments
  11. Other $357 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,122 111 payments
  2. Education $173 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $694 36 payments
  2. ILUMYA $112 5 payments
  3. ADBRY $108 4 payments
  4. SKYRIZI $101 4 payments
  5. DUPIXENT Inflammation And Immunology $96 5 payments
  6. SOTYKTU $93 5 payments
  7. COSENTYX $89 4 payments
  8. RINVOQ $88 4 payments
  9. EUCRISA $86 4 payments
  10. DUPIXENT Immunology $69 3 payments
  11. Other $1,156 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

899

Median for Dermatology: 534

Drug cost

$227,220

Median for Dermatology: $67,151

Branded share of claims

10.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 53 $201,299
Fluorouracil Generic 99 $5,344
Tacrolimus Generic 18 $3,324
Clobetasol Propionate Generic 55 $2,752
Triamcinolone Acetonide Generic 160 $2,439
Metronidazole Generic 40 $2,176
Clindamycin Phosphate Generic 54 $2,131
Ketoconazole Generic 81 $1,522
Fluocinonide Generic 17 $1,250
Imiquimod Generic 23 $853

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$136,211

Medicare's payments for the services billed

Medicare patients

920

Average age 75

Services billed

2,859

467 women, 453 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 40%
Ischemic heart disease 37%
Cancer 21%
Diabetes 20%
Osteoporosis 20%
Atrial fibrillation 17%
Chronic kidney disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatopathology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record